Literature DB >> 23372337

Report of incidence and mortality in China cancer registries, 2009.

Wanqing Chen1, Rongshou Zheng, Siwei Zhang, Ping Zhao, Guanglin Li, Lingyou Wu, Jie He.   

Abstract

OBJECTIVE: The National Central Cancer Registry (NCCR) collected cancer registration data in 2009 from local cancer registries in 2012, and analyzed to describe cancer incidence and mortality in China.
METHODS: On basis of the criteria of data quality from NCCR, data submitted from 104 registries were checked and evaluated. There were 72 registries' data qualified and accepted for cancer registry annual report in 2012. Descriptive analysis included incidence and mortality stratified by area (urban/rural), sex, age group and cancer site. The top 10 common cancers in different groups, proportion and cumulative rates were also calculated. Chinese population census in 1982 and Segi's population were used for age-standardized incidence/mortality rates.
RESULTS: All 72 cancer registries covered a total of 85,470,522 population (57,489,009 in urban and 27,981,513 in rural areas). The total new cancer incident cases and cancer deaths were 244,366 and 154,310, respectively. The morphology verified cases accounted for 67.23%, and 3.14% of incident cases only had information from death certifications. The crude incidence rate in Chinese cancer registration areas was 285.91/100,000 (males 317.97/100,000, females 253.09/100,000), age-standardized incidence rates by Chinese standard population (ASIRC) and by world standard population (ASIRW) were 146.87/100,000 and 191.72/100,000 with the cumulative incidence rate (0-74 age years old) of 22.08%. The cancer incidence and ASIRC were 303.39/100,000 and 150.31/100,000 in urban areas whereas in rural areas, they were 249.98/100,000 and 139.68/100,000, respectively. The cancer mortality in Chinese cancer registration areas was 180.54/100,000 (224.20/100,000 in males and 135.85/100,000 in females), age-standardized mortality rates by Chinese standard population (ASMRC) and by world standard population (ASMRW) were 85.06/100,000 and 115.65/100,000, and the cumulative incidence rate (0-74 age years old) was 12.94%. The cancer mortality and ASMRC were 181.86/100,000 and 80.86/100,000 in urban areas, whereas in rural areas, they were 177.83/100,000 and 94.40/100,000 respectively. Lung cancer, gastric cancer, colorectal cancer, liver cancer, esophageal cancer, pancreas cancer, encephaloma, lymphoma, female breast cancer and cervical cancer, were the most common cancers, accounting for 75% of all cancer cases in urban and rural areas. Lung cancer, gastric cancer, liver cancer, esophageal cancer, colorectal cancer, pancreatic cancer, breast cancer, encephaloma, leukemia and lymphoma accounted for 80% of all cancer deaths. The cancer spectrum showed difference between urban and rural areas, males and females. The main cancers in rural areas were cancers of the stomach, followed by esophageal cancer, lung cancer, liver cancer and colorectal cancer, whereas the main cancer in urban areas was lung cancer, followed by liver cancer, gastric cancer and colorectal cancer.
CONCLUSIONS: The coverage of cancer registration population has been increasing and data quality is improving. As the basis of cancer control program, cancer registry plays an important role in making anti-cancer strategy in medium and long term. As cancer burdens are different between urban and rural areas in China, prevention and control should be implemented based on practical situation.

Entities:  

Keywords:  Cancer registry; China; epidemiology; incidence; mortality

Year:  2013        PMID: 23372337      PMCID: PMC3555299          DOI: 10.3978/j.issn.1000-9604.2012.12.04

Source DB:  PubMed          Journal:  Chin J Cancer Res        ISSN: 1000-9604            Impact factor:   5.087


  5 in total

Review 1.  The evolution of the population-based cancer registry.

Authors:  Donald M Parkin
Journal:  Nat Rev Cancer       Date:  2006-08       Impact factor: 60.716

2.  Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness.

Authors:  Inger Kristin Larsen; Milada Småstuen; Tom Børge Johannesen; Frøydis Langmark; Donald Maxwell Parkin; Freddie Bray; Bjørn Møller
Journal:  Eur J Cancer       Date:  2008-12-16       Impact factor: 9.162

3.  [Trend analysis of cancer mortality in China between 1989 and 2008].

Authors:  Hong-mei Zeng; Rong-shou Zheng; Si-wei Zhang; Ping Zhao; Jie He; Wan-qing Chen
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2012-07

4.  [Trend analysis and projection of cancer incidence in China between 1989 and 2008].

Authors:  Wan-qing Chen; Rong-shou Zheng; Hong-mei Zeng; Si-wei Zhang; Ping Zhao; Jie He
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2012-07

5.  Representativeness of population-based cancer registration in China--comparison of urban and rural areas.

Authors:  Guang Lin Li; Wan Qing Chen
Journal:  Asian Pac J Cancer Prev       Date:  2009 Oct-Dec
  5 in total
  152 in total

1.  The STORM trial and beyond: narrowing the horizon of adjuvant sorafenib for postoperative hepatocellular carcinoma.

Authors:  Jian-Hong Zhong
Journal:  Tumour Biol       Date:  2015-11

2.  Genetic variations in MTHFR and esophageal squamous cell carcinoma susceptibility in Chinese Han population.

Authors:  Weifeng Tang; Sheng Zhang; Hao Qiu; Lixin Wang; Bin Sun; Jun Yin; Haiyong Gu
Journal:  Med Oncol       Date:  2014-04-01       Impact factor: 3.064

3.  Specific immunotherapy generates CD8(+) CD196(+) T cells to suppress lung cancer growth in mice.

Authors:  Jian Zhang; Jing Liu; Huiguo Chen; Weibin Wu; Xiaojun Li; Yonghui Wu; Zhigang Wang; Kai Zhang; Yun Li; Yimin Weng; Hongying Liao; Lijia Gu
Journal:  Immunol Res       Date:  2016-08       Impact factor: 2.829

4.  Ataxin-3 expression correlates with the clinicopathologic features of gastric cancer.

Authors:  Li-Xia Zeng; Yong Tang; Yun Ma
Journal:  Int J Clin Exp Med       Date:  2014-04-15

Review 5.  Anti-EGFR and anti-VEGF agents: important targeted therapies of colorectal liver metastases.

Authors:  Qing-Yang Feng; Ye Wei; Jing-Wen Chen; Wen-Ju Chang; Le-Chi Ye; De-Xiang Zhu; Jian-Min Xu
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

6.  China's landscape in oncology drug research: perspectives from research collaboration networks.

Authors:  Han You; Jingyun Ni; Michael Barber; Thomas Scherngell; Yuanjia Hu
Journal:  Chin J Cancer Res       Date:  2015-04       Impact factor: 5.087

Review 7.  Ambient air pollution and lung disease in China: health effects, study design approaches and future research.

Authors:  Jeffrey H Mandel; Christine Wendt; Charles Lo; Guangbiao Zhou; Marshall Hertz; Gurumurthy Ramachandran
Journal:  Front Med       Date:  2015-06-18       Impact factor: 4.592

8.  De novo malignancy after liver transplantation: a single-center experience of 14 cases.

Authors:  Peng Ji Gao; Jie Gao; Zhao Li; Zhi Ping Hu; Ji Ye Zhu
Journal:  Ann Surg Treat Res       Date:  2015-03-26       Impact factor: 1.859

9.  A study of "cancer villages" in Jiangsu Province of China.

Authors:  Yuanyuan Cheng; C Paul Nathanail
Journal:  Environ Sci Pollut Res Int       Date:  2018-11-20       Impact factor: 4.223

10.  TMP21 modulates cell growth in papillary thyroid cancer cells by inducing autophagy through activation of the AMPK/mTOR pathway.

Authors:  Xiaobo Xu; Hongqiang Gao; Jian Qin; Liu He; Wenyong Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.